Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

The following is a summary of “Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...

WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds.

a randomized phase III trial of carboplatin- or cisplatin-pemetrexed-pembrolizumab versus carboplatin- or cisplatin-pemetrexed in 492 patients with stage IV nonsquamous non–small cell lung cancer ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...